HRP20050027A2 - Azabicyclo-octane and nonane derivatives with ddp-iv inhibiting activity - Google Patents
Azabicyclo-octane and nonane derivatives with ddp-iv inhibiting activity Download PDFInfo
- Publication number
- HRP20050027A2 HRP20050027A2 HR20050027A HRP20050027A HRP20050027A2 HR P20050027 A2 HRP20050027 A2 HR P20050027A2 HR 20050027 A HR20050027 A HR 20050027A HR P20050027 A HRP20050027 A HR P20050027A HR P20050027 A2 HRP20050027 A2 HR P20050027A2
- Authority
- HR
- Croatia
- Prior art keywords
- group
- general formula
- meaning
- formula
- compounds
- Prior art date
Links
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 7
- QUIJMHDIAFOPRK-UHFFFAOYSA-N 1-cyclooctylazocane Chemical compound C1CCCCCCC1N1CCCCCCC1 QUIJMHDIAFOPRK-UHFFFAOYSA-N 0.000 title 1
- BKIMMITUMNQMOS-UHFFFAOYSA-N nonane Chemical class CCCCCCCCC BKIMMITUMNQMOS-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 70
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 claims abstract description 11
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 claims abstract 5
- -1 cinolylnyl Chemical group 0.000 claims description 53
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 20
- 150000003839 salts Chemical class 0.000 claims description 17
- 125000005843 halogen group Chemical group 0.000 claims description 16
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 14
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 14
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 13
- 125000005530 alkylenedioxy group Chemical group 0.000 claims description 12
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 12
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- 239000012453 solvate Substances 0.000 claims description 11
- 125000004076 pyridyl group Chemical group 0.000 claims description 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 9
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 claims description 9
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims description 9
- 150000004677 hydrates Chemical class 0.000 claims description 7
- ALSCEGDXFJIYES-UHFFFAOYSA-N pyrrolidine-2-carbonitrile Chemical compound N#CC1CCCN1 ALSCEGDXFJIYES-UHFFFAOYSA-N 0.000 claims description 7
- 239000011541 reaction mixture Substances 0.000 claims description 7
- 125000004953 trihalomethyl group Chemical group 0.000 claims description 7
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 claims description 6
- 125000005956 isoquinolyl group Chemical group 0.000 claims description 6
- 125000001624 naphthyl group Chemical group 0.000 claims description 6
- 125000005493 quinolyl group Chemical group 0.000 claims description 6
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 5
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims description 5
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 4
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 4
- 125000003277 amino group Chemical group 0.000 claims description 3
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 3
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 claims description 3
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 3
- 125000002541 furyl group Chemical group 0.000 claims description 3
- 125000000623 heterocyclic group Chemical group 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 125000002883 imidazolyl group Chemical group 0.000 claims description 3
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 3
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 3
- 125000001786 isothiazolyl group Chemical group 0.000 claims description 3
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 3
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims description 3
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 3
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 3
- 125000002971 oxazolyl group Chemical group 0.000 claims description 3
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 3
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 3
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 3
- 125000000335 thiazolyl group Chemical group 0.000 claims description 3
- 125000001544 thienyl group Chemical group 0.000 claims description 3
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 1
- 230000002255 enzymatic effect Effects 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000006253 t-butylcarbonyl group Chemical group [H]C([H])([H])C(C(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 238000010276 construction Methods 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 102
- 239000000243 solution Substances 0.000 description 56
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 42
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 42
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 42
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 40
- 239000000203 mixture Substances 0.000 description 28
- 238000005160 1H NMR spectroscopy Methods 0.000 description 26
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 19
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 18
- 239000000047 product Substances 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 239000003480 eluent Substances 0.000 description 14
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- 229910052938 sodium sulfate Inorganic materials 0.000 description 12
- 235000011152 sodium sulphate Nutrition 0.000 description 12
- 239000013078 crystal Substances 0.000 description 11
- 239000000725 suspension Substances 0.000 description 11
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 10
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 10
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 10
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 238000004440 column chromatography Methods 0.000 description 9
- 239000003921 oil Substances 0.000 description 9
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 8
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 5
- GLNDAGDHSLMOKX-UHFFFAOYSA-N coumarin 120 Chemical compound C1=C(N)C=CC2=C1OC(=O)C=C2C GLNDAGDHSLMOKX-UHFFFAOYSA-N 0.000 description 5
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 4
- 239000012230 colorless oil Substances 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- WPMZIZVPJORINX-RXMQYKEDSA-N (4r)-3-(2-chloroacetyl)-1,3-thiazolidine-4-carbonitrile Chemical compound ClCC(=O)N1CSC[C@H]1C#N WPMZIZVPJORINX-RXMQYKEDSA-N 0.000 description 3
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- CSTBBLHIGMTEAZ-UHFFFAOYSA-N chloroform;ethyl acetate;hexane Chemical compound ClC(Cl)Cl.CCCCCC.CCOC(C)=O CSTBBLHIGMTEAZ-UHFFFAOYSA-N 0.000 description 3
- 239000002178 crystalline material Substances 0.000 description 3
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 230000020477 pH reduction Effects 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 238000011533 pre-incubation Methods 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- MZDGWSZDVNMGRC-YFKPBYRVSA-N (2s)-1-(2-chloroacetyl)-2,5-dihydropyrrole-2-carboxamide Chemical compound NC(=O)[C@@H]1C=CCN1C(=O)CCl MZDGWSZDVNMGRC-YFKPBYRVSA-N 0.000 description 2
- NRDOQMABVJRPFF-WCCKRBBISA-N (2s)-2,5-dihydro-1h-pyrrole-2-carboxamide;hydrochloride Chemical compound Cl.NC(=O)[C@H]1NCC=C1 NRDOQMABVJRPFF-WCCKRBBISA-N 0.000 description 2
- PBEKPIGIRCUVGJ-NTSWFWBYSA-N (2s,4r)-1-(2-chloroacetyl)-4-hydroxypyrrolidine-2-carbonitrile Chemical compound O[C@@H]1C[C@@H](C#N)N(C(=O)CCl)C1 PBEKPIGIRCUVGJ-NTSWFWBYSA-N 0.000 description 2
- LIGUILWQVCSNPO-ZBTZCESGSA-N (2s,4r)-4-hydroxypyrrolidine-2-carbonitrile;4-methylbenzenesulfonic acid Chemical compound O[C@H]1CN[C@H](C#N)C1.CC1=CC=C(S(O)(=O)=O)C=C1 LIGUILWQVCSNPO-ZBTZCESGSA-N 0.000 description 2
- SWTCRXVGKJOXJA-DFWYDOINSA-N (4r)-1,3-thiazolidine-4-carboxamide;hydrochloride Chemical compound Cl.NC(=O)[C@@H]1CSCN1 SWTCRXVGKJOXJA-DFWYDOINSA-N 0.000 description 2
- MYIZVBUUNYRQLA-BYPYZUCNSA-N (4r)-3-(2-chloroacetyl)-1,3-thiazolidine-4-carboxamide Chemical compound NC(=O)[C@@H]1CSCN1C(=O)CCl MYIZVBUUNYRQLA-BYPYZUCNSA-N 0.000 description 2
- ZQYVRUHRNHIWMF-DFWYDOINSA-N (4s)-1,3-oxazolidine-4-carboxamide;hydrochloride Chemical compound Cl.NC(=O)[C@@H]1COCN1 ZQYVRUHRNHIWMF-DFWYDOINSA-N 0.000 description 2
- BQGUYWPCWNWFJV-YFKPBYRVSA-N (4s)-3-(2-chloroacetyl)-1,3-oxazolidine-4-carbonitrile Chemical compound ClCC(=O)N1COC[C@@H]1C#N BQGUYWPCWNWFJV-YFKPBYRVSA-N 0.000 description 2
- YXZREQZWFIDHNN-BYPYZUCNSA-N (4s)-3-(2-chloroacetyl)-1,3-oxazolidine-4-carboxamide Chemical compound NC(=O)[C@@H]1COCN1C(=O)CCl YXZREQZWFIDHNN-BYPYZUCNSA-N 0.000 description 2
- SCZNXLWKYFICFV-UHFFFAOYSA-N 1,2,3,4,5,7,8,9-octahydropyrido[1,2-b]diazepine Chemical compound C1CCCNN2CCCC=C21 SCZNXLWKYFICFV-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 108010004460 Gastric Inhibitory Polypeptide Proteins 0.000 description 2
- 102100039994 Gastric inhibitory polypeptide Human genes 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000008351 acetate buffer Substances 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000012089 stop solution Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- ISGKNURQVBUGBO-RQJHMYQMSA-N tert-butyl (2s,4r)-2-carbamoyl-4-hydroxypyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1C[C@H](O)C[C@H]1C(N)=O ISGKNURQVBUGBO-RQJHMYQMSA-N 0.000 description 2
- OXGKKJVYQKKOIS-LURJTMIESA-N tert-butyl (4r)-4-carbamoyl-1,3-thiazolidine-3-carboxylate Chemical compound CC(C)(C)OC(=O)N1CSC[C@H]1C(N)=O OXGKKJVYQKKOIS-LURJTMIESA-N 0.000 description 2
- HAPBJEQPKUGZEB-LURJTMIESA-N tert-butyl (4s)-4-carbamoyl-1,3-oxazolidine-3-carboxylate Chemical compound CC(C)(C)OC(=O)N1COC[C@H]1C(N)=O HAPBJEQPKUGZEB-LURJTMIESA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- NWMCUKZFZXKSPU-LURJTMIESA-N (2s)-1-(2-chloroacetyl)-2,5-dihydropyrrole-2-carbonitrile Chemical compound ClCC(=O)N1CC=C[C@H]1C#N NWMCUKZFZXKSPU-LURJTMIESA-N 0.000 description 1
- YCWRPKBYQZOLCD-LURJTMIESA-N (2s)-1-(2-chloroacetyl)pyrrolidine-2-carbonitrile Chemical compound ClCC(=O)N1CCC[C@H]1C#N YCWRPKBYQZOLCD-LURJTMIESA-N 0.000 description 1
- OMGHIGVFLOPEHJ-BYPYZUCNSA-N (2s)-2,5-dihydro-1h-pyrrole-2-carboxylic acid Chemical compound OC(=O)[C@H]1NCC=C1 OMGHIGVFLOPEHJ-BYPYZUCNSA-N 0.000 description 1
- QOIGPIUFRWWRMS-RQJHMYQMSA-N (2s,4r)-1-(2,2-dimethylpropanoyl)-4-hydroxypyrrolidine-2-carboxylic acid Chemical compound CC(C)(C)C(=O)N1C[C@H](O)C[C@H]1C(O)=O QOIGPIUFRWWRMS-RQJHMYQMSA-N 0.000 description 1
- FJWNZTPXVSWUKF-LURJTMIESA-N (4r)-3-[(2-methylpropan-2-yl)oxycarbonyl]-1,3-thiazolidine-4-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CSC[C@H]1C(O)=O FJWNZTPXVSWUKF-LURJTMIESA-N 0.000 description 1
- LFAOMDJJZKWOPH-LURJTMIESA-N (4s)-3-[(2-methylpropan-2-yl)oxycarbonyl]-1,3-oxazolidine-4-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1COC[C@H]1C(O)=O LFAOMDJJZKWOPH-LURJTMIESA-N 0.000 description 1
- PRSDPVKGJUBIAA-UHFFFAOYSA-N 1,3-thiazolidine-4-carbonitrile Chemical compound N#CC1CSCN1 PRSDPVKGJUBIAA-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- BAZVFQBTJPBRTJ-UHFFFAOYSA-N 2-chloro-5-nitropyridine Chemical compound [O-][N+](=O)C1=CC=C(Cl)N=C1 BAZVFQBTJPBRTJ-UHFFFAOYSA-N 0.000 description 1
- GELVZYOEQVJIRR-UHFFFAOYSA-N 2-chloropyrazine Chemical compound ClC1=CN=CC=N1 GELVZYOEQVJIRR-UHFFFAOYSA-N 0.000 description 1
- UNCQVRBWJWWJBF-UHFFFAOYSA-N 2-chloropyrimidine Chemical compound ClC1=NC=CC=N1 UNCQVRBWJWWJBF-UHFFFAOYSA-N 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- VSCBATMPTLKTOV-UHFFFAOYSA-N 2-tert-butylimino-n,n-diethyl-1,3-dimethyl-1,3,2$l^{5}-diazaphosphinan-2-amine Chemical compound CCN(CC)P1(=NC(C)(C)C)N(C)CCCN1C VSCBATMPTLKTOV-UHFFFAOYSA-N 0.000 description 1
- FHNCCAGEZMNIHZ-UHFFFAOYSA-N 3,4,5,5a,6,7,8,9-octahydro-2h-1,2-benzodiazepine Chemical compound N1CCCC2CCCCC2=N1 FHNCCAGEZMNIHZ-UHFFFAOYSA-N 0.000 description 1
- ORIQLMBUPMABDV-UHFFFAOYSA-N 6-chloropyridine-3-carbonitrile Chemical compound ClC1=CC=C(C#N)C=N1 ORIQLMBUPMABDV-UHFFFAOYSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 108010088406 Glucagon-Like Peptides Proteins 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 101000908391 Homo sapiens Dipeptidyl peptidase 4 Proteins 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 239000003810 Jones reagent Substances 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 206010049287 Lipodystrophy acquired Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 208000034493 Mucous membrane disease Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 101710176384 Peptide 1 Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 238000006254 arylation reaction Methods 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 125000005518 carboxamido group Chemical group 0.000 description 1
- 230000003683 cardiac damage Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000014101 glucose homeostasis Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000005929 isobutyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])OC(*)=O 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 1
- 210000000231 kidney cortex Anatomy 0.000 description 1
- 208000006132 lipodystrophy Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004742 propyloxycarbonyl group Chemical group 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 239000003586 protic polar solvent Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000004032 superbase Substances 0.000 description 1
- 150000007525 superbases Chemical class 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- LGJDOIHXXBPYBN-ZETCQYMHSA-N tert-butyl (2s)-2-carbamoyl-2,5-dihydropyrrole-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC=C[C@H]1C(N)=O LGJDOIHXXBPYBN-ZETCQYMHSA-N 0.000 description 1
- UNVNZVOSYRUJTH-JGVFFNPUSA-N tert-butyl (2s,4r)-2-cyano-4-hydroxypyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1C[C@H](O)C[C@H]1C#N UNVNZVOSYRUJTH-JGVFFNPUSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/04—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D263/06—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by oxygen atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D277/06—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
Abstract
Prezentirani izum odnosi se na nave spojeve opće formule (I) koji posjeduju inhibitorno djelovanje za DPP-IV. Ti spojevi sadržavaju tropan blokove zaizgradnju.
Description
Prezentirani izum se odnosi na nove spojeve opće formule (I) koji imaju dipeptidil-peptidaza-IV enzim inhibicijsko djelovanje, kao i na njihove soli, solvate i izomere, na farmaceutske sastave koji ih sadržavaju, na terapijsku aplikaciju spojeva opće formule (I), na postupak proizvodnje spojeva opće formule (I) i nove intermedijere opće formule (II), (IV), (V), (VII), (VIII) i (IX).
Enzim, dipeptidil-peptidaza-IV (DPP-IV), koji je istovjetan s glikoproteinom CD26 površine limfocita, polipeptidom molekulske mase od 110 k Daltona, a formira se u tkivima i organima sisavaca. Ti enzimi mogu se naći, i drugdje, u jetri, u Langerhansovim kanalima, u korteksu bubrega, u plućima, i određenim tkivima prostate i tankog crijeva. Nadalje je značajno DPP-IV djelovanje može se uočiti i u tjelesnim tekućinama (na primjer u plazmi, serumu i urinu).
DPP-IV je serin proteaza tip enzima, koji ima jedinstvenu specifičnost za cijepanje dipeptida od N-krajeva peptida, gdje predzadnja amino kiselina je uglavnom prolin alanin ili hidroksi-prolin.
DPP-IV enzim je odgovoran za dekompoziciju glukagonu sličnih polipeptida, peptida-1 (GLP-1) i GIP (gastric inhibitorv polipeptid) u organizmu. Enzim GLP-1 snažno stimulira produkciju inzulina u pankreasu, pa tako direktno, povoljno djeluje na homeostazu glukoze, zato su DPP-IV inhoibitori pogodni za tretiranje dijabetes melitusa koji ne ovisi o inzulinu (NIDDM) i drugih bolesti povezanih s djelovanjem DPP-IV enzima uključujući ali ne ograničavajući na dijabetes, pretilost, hiperlipidemiju, poremetnje dermatoloških ili mukoznih membrana, psorijazu, intestinalne bolove, konstipaciju, autoimune poremećaje kao i encefalomijelitis, komplementarno posredovane poremećaje kao i glomerulonefritis, lipodistrofija, i oštećenja tkiva, psihosomatske, depresivne i neuropsihijatrijske bolesti kao i anksioznost, depresija, insomija, shizofrenija, epilepsija, spazam, i komične bolove, HIV infekcija, alergije, upale, artritis, odbacivanje tkiva nakon transplantacije,visioki krvni tlak, kongestivna oštećenja srca, tumori, i abortusi uzrokovani stresom. U literaturi su poznati brojni DPP-IV inhibitori, ali oni imaju nedostatak s obzirom na njihov aktivitet, toksičnost, stabilitet i duljinu trajanja djelovanja.
Naš cilj je proizvesti nove, učinkovite DPP-IV inhibitore. Utvrdili smo da novi spojevi opće formule (I) gdje R stoji za:
- aromatski dio s jednim ili dva prstena koji sadržavaju dušik, preferirano piridil, piridazinil, pirimidinil, pirazinil, imidazolil, pirazolil, tiazolil, izotiazolil, oksazolil, izoksazolil, oksadiazolil, kvinolinil, izokvinolinil, cinolilnil, ftalazinil, kvinazolinil, kvinoksalinil, benzimidazolil, indazolil, benzotiazolil, benzisotiazolil, benzoksazolil ili benzisoksazolil dio koji je po izboru mono- ili disubstituiran neovisno s jednom ili dvije od slijedećih skupina: C1-4 alkil skupinom, C1-4 alkoksi skupinom, atomom halogena, atom halogena, trihalogenmetil skupinom, metiltio skupinom, nitro skupinom, cijano skupinom, C2-5 alkoksikarbonil skupinom ili karboksamino skupinom, ili
- p-tolilsulfonil skupina, ili
- R1a-CH2-skupina, gdje je značenje R1a vodik, C1-4 alkil skupina, fenil, benzil, feniletil, naftil, piridil, kvinolil, izokvinolil/ cinolinil, ftalazinil, kvinazolinil, kvinoksalinil, tienil, furil ili p-toluensulfonil dio nezavisno substituiran s jednom ili više C1-4 alkil skupina, C1-4 alkoksi skupinom, alkilendioksi skupinom, atomom halogena, trihalogenmetil, nitro ili cijano skupinom, ili
-R1b-CO-skupina, gdje je značenje R1b C1-4 alkil skupina, fenil, benzil, feniletil, feniletenil, naftil, piridil, kvinolil, izokvinolil, cinolinil, ftalazinil, kvinazolinil ili kvinaksalinil dio substituiran nezavisno s jednom ili više C1-4 alkil skupina, C1-4 alkoksi skupina, alkilendioksi skupinom, atomom halogena, trihalogenmetil, nitro ili cijano skupinom, mono- ili disupstituiran amino skupinom, zasićenim heterocikličnim dijelom koji sadržava N, preferirano sa skupinom koja sadržava pirolidino, piperidino, piperazino ili morfolino prsten;
B stoji za skupinu u skladu s formulom (1) ili (2) ili (3) ili (4);
Z stoji za skupine formule (A) ili (B) ili (C) ili (D) ili (E) ili (F);
i soli, izomere, tautomere, hidrate ili solvate gore navedenih spojeva koji posjeduju značajne prednosti u njihovom djelovanju, stabilnosti ili toksičnosti.
U skladu s prihvaćenom terminologijom, konfiguracija atoma ugljika do dušika u pentacikličnom prstenu koji sadržava N preporučljivo je R ako Z stoji za formulu (A) i preporučljivo je S ako Z stoji za (B), (C), (D), (E), ili (F). Pojam „atom halogena" znači atom fluora, klora, broma ili joda. Pojam „C1-4 alkil skupina" znači metil, etil, propil, izopropil, n-butil, izobutil ili tert.-butil skupina. Pojam „C1-4 alkoksi skupina" znači metoksi, etoksi, propoksi, izopropoksi, n-butoksi, izobutoksi ili tert.-butoksi skupina. U pojmu „trihalogenmetil skupina" halogeni znače fluor, klor, brom ili jod. Pojam „C2-5 alkoksikarbonil" znači metoksikarbonil, etoksikarbonil, propoksikarbonil, izopropoksikarbonil, n-butoksikarbonil, izobutoksikarbonil ili tert.-butokiskarbonil skupina. Jedna od skupina opće formule (I) koje imaju prednost gdje R znači pirimidinil-, piridinil-, pirazinil, piridazinil-, bnezotiazolil-, benzisotiazolil-, benzoksazolil-, benzisoksazolil-skupina koja je u navedenom slučaju od bilo kojeg drugogh mono- ili disubstituioranog s jednom ili više slijedećih skupina: C1-4 alkil skupine, C1-4 alkoksi skupine, atoma halogena, nitro skupine, cijano skupine, C2-5 alkoksikarbonil skupine ili karboksamido skupine, ili
p-tolilsulfonil-skupine; ili
R1a-CH2-skupina gdje je značenje R1a benzil skupina ili feniletil skupina substituiranau navedenom slučaju nezavisno s jednom ili više Cl-4 alkil ili alkilen dioksi skupina; ili R1bCO-skupina gdje je značenje R1b fenil, benzil, feniletil, feniletenil ili piperidino skupina koja je u navedenom slučaju nezavisno substituirana od jedne druge s alkilendioksi skupine;
B stoji za skupinu formule (1) ili (2) ili (3) ili (4);
Z stoji za skupinu formule (A) ili formule (B) ; i njihove soli, izomere, tautomere, hidrate ili solvate.
Osobitu prednost imaju spojevi opće formule (I) gdje je značenje R 2-pirimidil, 2-piridazil ili 2-piridil skupina substituirana s nitro ili cijano skupinom a Z stoji za formulu (A) ili (B) ; takvi spojevi su na primjer (4R)-3-(2-{[8-(2-pirimidinil) -8-azabiciklo [3.2.1]okt-3-il] ekso-amino}acetil) -tiazolidin-4-karbonitril, (4R)-3-(2-{[8-(5-cijano-piridin-2-il)-8-azabiciklo [3.2.1] oktan-3-il] ekso-amino}acetil) -tiazolidin-4-karbonitril, (4R)-3-(2-{[8-(5-cijanopiridin-2-il)-8-azabiciklo[3.2.1]oktan-3-il]endo-amino}acetil)tiazolidin-4-karbonitril, (4R)-3-(2-{[8-(2-pirazinil)-8-azabiciklo[3.2.1]oktan-3-il]ekso-amino}acetil)-tiazolidin-4-karbonitril i (2S)-1-(2-{[8-(5-nitropiridin-2-il)-8-azabiciklo[3.2.1]oktan-3-il]ekso-amino}acetil) -pirolidin-2-karbonitril.
Spojeve opće formule (I) u skladu s izumom - gdje je značenje R i B i Z kao što je definirano gore - može se proizvesti alkilacijom primarnih cikličnih amina opće formule (II) s derivatima kloracetilkarbonitrila opće formule (III) - gdje je značenje B i Z kao što je definirano gore - i ako se zahtjeva, nastali spojevi se transformiraju u njihove soli ili solvate (Shema 1).
Za vrijeme alkilacije derivati kloracetilkarbonitrila opće formule (III) ili ciklični primarni amini opće formule (II) koriste se u suvišku, a nastali vodikov klorid se veže s različitim sredstvima za vezivanje kiselina, preferirano na osnovi, kao što su na primjer 1,8-diazabiciklo[5.4.0]undec-7-ena (DBU), trietilamina, kalij karbonata ili polimer poduprt s 2-terc-butilimino-2-dietilamino-1,3-dimetil-perhidro-1,3,2-diazafosforinom (PBEMP), koji je poznat kao super baza. Reakcija se preferirano izvodi na temperaturi između 25 i 75°C tijekom 3 -16 sati.
Primarni amini opće formule (II) su proizvedeni u dvo-faznoj sintezi (Shema 2). U prvoj fazi starta se s zaštićenim cikličnim sekundarnim aminom -spoj opće formule (IV), gdje Y stoji za tert-butoksikarbonil skupinu -je arilirana sa spojem opće formule (X), gdje je X atom halogena u R-X spojevima, prefreirano atom klora ili broma. Ovisno o značenju R, arilacija se može izvesti u polarnom, protičkom ili aprotičkom otapalu, preferirano u alkoholu (etanol, n-butanol, n-pentanol), na temperaturi između 78 i 136°C, ili bez otapala, u mikrovalnoj pećnici, upotrebom amina ili DBU u suvišku kao sredstva za vezanje.
Za polazni materijal zaštićeni ciklični sekundarni amin opće formule (IV) - poznato je iz literature -da se koristi, tert-butil 8-azabiciklo [3.2.1]okt-2-il-ekso-karbamat (B = formula (1)) i tert-butil 8-aza-biciklo[3.2.1]okt-3-il-endo-karbamat (B = formula (2)) (J.Med. Chem. 1991, 34, 656), ili tert-butil 9-azabiciklo-[3.3.1]non-3-il-ekso-karbamat (B = formula (3)) i tert-butil 9-azabiciklo-[3.3.l]non-3-il-endo-karbamat (B formula (4)) (J.Med. Chem. 1993, 36, 3707)) (Y = tert-butoksikarbonil skupina).
U drugom koraku zaštitna Y skupina se odstrani kiselom hidrolizom od ariliranog amina opće formule (V) - gdje značenje R i Y su kao što je definirano gore. Reakcija se izvodi u vodenoj klorovodičnoj kiselini ili u etanolnoj otopini klorovodika, na temperaturi između 25 i 78°C, za proizvodnju cikličnog primarnog amina opće formule (II) -gdje je značenje R isto kao što je gore definirano.
U slučaju kada je R R1a-CH2- ili R1b-CO skupina, spoj opće formule (IV) reagira sa spojem opće formule (X), odnosno R1a-CH2X ili R1b-COX spojem - gdje je značenje X ostatna skupina, preferirano atom klora, poželjno na temperaturi oko 0°C, upotrebom anorganske ili organske baze, preferirano trietilamin kao kiselo sredstvo za vezanje. Od nastalog spoja opće formule (V) zaštitna skupina Y - gdje je značenje Y tert-butoksikarbonil skupina - je odcijepljena u kiselim uvjetima, preferirano s trifluoroctenom kiselinom u otopini diklormetana, na temperaturi između 0°C i 30°C, da bi se dobio spoj opće formule (II) - gdje je značenje R R1a-CH2- ili R1b-CO- skupina.
Kloracetilcijano spojevi opće formule (III) - gdje je značenje Z kao što je definirano gore - je poznato (Z = (B)i Villhauer et al., J.Med.Chem. 2002, 45, 2362) ili proizveden sintezom u četiri faze (Shema 3).
Polazni materijali su pentaciklična kiselina koja sadržava N s dušikom zaštićenim s tert-butoksikarbonil skupinom - spojevima opće formule (VI) - gdje je značenje Z kao što je definirano gore. Ti spojevi mogu se proizvesti postupcima poznatim u literaturi (Z = (A): J.Kitcin et al. J.Med.Chem. 1994, 31, 3707; Z = (C): S.Conti et al. Tetrahedron 1994, 50, 13493; Z = (D): S.C. Mayer et al. J.Org.Chem. 1994, 59, 5192)) ili komercijalno dostupnim (Z = (E): Aldrich).
U prvoj fazi pomiješani anhidrid je proizveden s pivaloil kloridom ili etil esterom kloroformne kiseline, potom derivatima karbamoila opće formule (VII) - gdje značenje Z je isto kao što je definirano gore - su formirani s vodenim amonijem. Reakcija se prefrirano izvodi u halogeniranom otapalu (kloroform, diklormetan) na -5°C u 2-4 sata reakcije.
U drugoj fazi tert-butoksikarbonil skupina se cijepa s etanolnom otopinom vodik klorida. Hidroliza se izvodi na 0-25°C tijekom 3 -5 sati a dobije se hidroklorid karboksamid opće formule (VIII) - gdje je značenje Z isto kao što je definirano gore.
Nastali pentaciklični karboksamid opće formule (VIII) se u tri faze acilira s kloracetil kloridom, preferirano na 0°C u halogeniranom otapalu (kloroform, diklormetan) tijekom 2-4 sata da se dobiju derivati kloracetilkarbamoila opće formule (IX) -gdje je značenje Z isto kao što je definirano gore.
U četvrtoj fazi derivati kloracteilkarbamoila opće formule (IX) - gdje je značenje Z kao što je definirano gore - se dehidrira da bi se dobilo derivate kloracetilkarbonitrila opće formule (II). Dehidracija se prefreirano izvodi s oksalil kloridom u DMF na tmeparturi ispod 0°C ili s fosfornim oksikloridom u diklormetanu na točki vrenja.
[image]
[image]
Biološka ispitivanja
DPP-IV enzimsko inhibitorno djelovanje spojeva opće formule (I) se određuje slijedećom metodom:
Primijenjeni uvjeti analize:
Izvor DPP-IV: otopljeni sirovi ekstrakt od CaCo/Tc-7-stanica
sadržaj: 0.8-1 μg/analiza
Substart: H-Gly-Pro-AMC (Bachem)
Reakcija: 1 sat predinkubacije s inhibtorima na 37°C,
30 min reakcijsko vrijeme na 37°C
Stop otopina: 1M Na-acetat pufer (pH=4.2)
Reakcijska smjesa: 10 μl otopine enzima
10 μl ispitivanog spoja ili pufera za analizu
55 μl pufera za analizu
25 μl substrata
300 μl stop otopine
Mjerenje: spektrofluorometrijskim određivanjem s Tekan čitačem ploča
(Ex: 360 nm Em: 465 nm)
Reakcija DPP-IV enzima i H-Gly-Pro-AMC substrata se bilježi oslobađanjem AMC (7-amino-4-metilkumarin) na 37°C u 100 mM -tris-HCl, pH=7.5 (pufer za analizu). Standardna krivulja AMC linearna je sve do 31.25 μM koncentracije, to je zato što koristimo relativnu fluorescencijsku jedinicu (RFU) za formiranje AMC. Određuje se upotrebom filtera 360 nm ekscitacije i 465 nm emisije (30 us vrijeme integracije, Gain -5, Br. plamena 50) s Tecan Spectrofluor Plus čitačem ploča. Uz te uvjete enzimska reakcija je linearna u zadnjih 30 min, a enzimska ovisnost linearna sve do 2.5 μg proteina (sve do 700 RFU). Koristeći 1-0.8 μg ekstrakta proteina Km za H-Gly-Pro-AMC je 50 μM. Više od 500 μM koncentracija substrata uzrokuje probleme s fluorescentnom detekcijom (unutarnji učinak filtera) može se riješiti razrjeđivanjem uzorka.
Analiza je dizajnirana tako da najučinkovitije određuje aktivnost inhibitora upotrebom 60 min predinkubacije na 37°C. Analiza se izvodi dodavanjem 0.8-1 ug proteinskog ekstrakta u 10 μl otopine enzima ( upotrebom pufera za analizu: 100 mM Tris-HCl, pH=7.5) u bunariće koji sadržavaju spojeve koji se ispituju u 10 μl volumena i 55 μl pufera za analizu (65 ul pufera za analizu u slučaju kontrole). Nakon razdoblja predinkubacije, reakcija počinje dodavanjem 25 pl otopine H-Gly-Pro-AMC substrata (250 μM finalna koncentracija). Finalni ispitivani volumen je 100 pl a otopina koja se ispituje sadržava 1% DMSO koji je od otopine spojeva koji se ispituju. Vrijeme reakcije je 30 min na 37°C, i reakcija se prekida dodavanjem 300 pl IM Na-acetat pufera, pH=4.2. Fluorescencija (RFU formiranog AMC se određuje upotrebom 360 nm ekscitacije i 465 emisije filtera u Tečan spectrofluor Plus čitaču ploča (30 μs vrijeme integracije, Gain 25 Br. plamena 50).
% inhibicije se izračunava upotrebom RFU kontrole i RFU slijepe probe.
IC5o vrijednost za inhibicijski učinak na enzim spojeva opće formule (I). Ti spojevi pokazuju nisku IC50 vrijednost u komparaciji s poznatim spojevima. To su jaki i dugo djelujući inhibitori enzima.
Spojevi opće formule (I) i njihove soli, solvati i izomere mogu se formulirati za oralnu ili parenteralnu aplikaciju farmaceutskih sastava od prije poznatim metodama, miješanjem s jednim ili više farmaceutski prihvatljivih pomoćnih materijala ili diluentom i mogu se aplicirati kao jedinično pakovanje za aplikaciju.
Odgovarajuće jedinično pakovanje obuhvaća oralne oblike, kao što su tablete, čvrste ili meke želatinozne kapsule, prašci, granule i oralne otopine ili suspenzije, sublingvalni, bukalni, intratrahealni, intraokularni, intranazalni oblici, s inhalacijskim, topičkim, transdermalnim, sub-kutanim, intramuskularnim ili intra-venoznim oblicima, rektalnim oblicima i implatantima. Za topičku aplikaciju spojevi izuma mogu se koristiti kao kreme, gelovi, pomade od losiona.
Kao primjer, jediničnog pakovanja za spoj u skladu s izumom u obliku tableta, može obuhvaćati slijedeće sastojke:
A spoj opće formule (I) 50.0 mg
Manitol 223.75 mg
Natrij kroskarmeloza 6.0 mg
Kukuruzni škrob 15.0 mg
Hidroksipropil metilceluloza 2.25 mg
Magnezij sterat 3.0 mg.
Dnevna doza spojeva opće formule (I) ovisi o brojnim faktorima, tako i o prirodi i težini bolesti pacijenta, o načinu aplikacije i o samom spoju.
Drugi detalji o izumu pokazani su na primjer u primjerima koji slijede, bez ograničavanja zahtijeva na primjere.
Slika 1 pokazuje spojeve opće formule (I),
Slika 2 pokazuje spojeve opće formule (II),
Slika 3 pokazuje spojeve opće formule (III),
Slika 4 pokazuje spojeve opće formule (IV),
Slika 5 pokazuje spojeve opće formule (V),
Slika 6 pokazuje spojeve opće formule (VI),
Slika 7 pokazuje spojeve opće formule (VII),
Slika 8 pokazuje spojeve opće formule (VIII),
Slika 9 pokazuje spojeve opće formule (IX),
Slika 10 pokazuje spojeve opće formule (X),
Slika 11 pokazuje formulu (1),
Slika 12 pokazuje formulu (2),
Slika 13 pokazuje formulu (3),
Slika 14 pokazuje formulu (4),
Slika 15 pokazuje formulu (A),
Slika 16 pokazuje formulu (B),
Slika 17 pokazuje formulu (C),
Slika 18 pokazuje formulu (D),
Slika 19 pokazuje formulu (E),
Slika 20 pokazuje formulu (F).
Primjer 1.
(4R)-3- (2-{[8- (2-pirimidinil)-8-azabiciklo [3.2.1] okt-3-il] ekso-amino)acetil)tiazolidin-4-karbonitril
Značenje R je 2-piridinil skupina, B znači skupinu formule (1), Z znači skupinu formule (A) u općoj formuli (I)
a.) tert-butil 8-(2-pirimidinil)-8-azabiciklo[3.2.1]okt-3-il-ekso-karbamat
s općom formulom (V) - gdje R i B su dati gore, Y je tert-butoksikarbonil skupina
14.7 g (65 mmol) tert-butil 8-azabiciklo [3.2.1] okt-3-il-ekso-karbamat (J.Med. Chem. 1991, 34, 656) i 8.93 g (78 mmol) 2-klorpirimidina i 12.7 ml (85 mmol) 1,8-diazabiciklo[5.4.0]undec-7-ena se rastopi u 230 ml n-pentanola i zagrije se do refluksa kroz 4 sata. Otapala se evaporiraju a ostatak se rastopi u 250 ml kloroforma i ispere s 2x300 ml vode, osuši iznad natrij sulfata, i purificira kolonskom kromatografijom upotrebom n-heksan-etil acetat-kloroform (1:1:1) kao eluenta što rezultira bijelim kristalima koji se usitne s n-heksanom. Prinos: 13.25 g (67%). T.t.: 113-115°C.
1H-NMR (CDCl3): δ 1.34 (s,9H), 1.49 (t,2H), 1.66-1.97 (m, 6H), 3.89 (br, 1H), 4.61 (d,2H), 6.60 (t+br, 1+1H), 8.34 (d,2H).
b.) 8- (2-pirimidinil) -8-azabiciklo [3.2.1] okt-3-il-ekso-amin
opće formule (II), gdje R i B su navedeni u prvoj fazi 1a.)
13 g (43 mmol) tert-butil 8-(2-pirimidinil)-8-azabiciklo [3.2.1] okt-3-il-ekso-karbamat se rastopi u smjesi od 120 ml trifluoroctene kiseline i 120 ml diklormetana. Otopina se miješa kroz 30 minuta i evaporira. Ostatak se rastopi u 50 ml diklormetana i evaporira. Ovaj postupak se ponovi tri puta a finalna organska otopina se ekstrahira sa 100 ml zasićene vodene otopine natrij karbonata. Slojevi se odvoje a vodena faza se ispere s 4x50 ml diklormetana. Spojeni organski slojevi se osuše iznad natrij sulfata i evaporiraju da bi se dobio bijeli prašak koji se usitni s n-heksanom. Prinos:6.7 g (77 %). T.t.: 56-59°C. lH-MMR (DMSO-d6) : δ 1.29 (t,2H), 1.64-1.98 (m,6H), 3.19 (m,1H), 4.58 (dd,2H), 6.57 (t,1H), 8.33 (d,2H).
c.) tert-butil (4R)-4-(aminokarbonil)tiazolidin-3-karboksilat
opće formule (VII), gdje Z znači skupinu formule (A)
11.1 g (47.6 mmol) (4R)-3-(tert-butoksikarbonil)tiazolidin-4-karboksilna kiselina (J.Med.Chem 1994, 37, 3707) se rastopi u 125 ml diklormetana i doda se 8 ml (57.5 mmol) trietilamina. U nastalu smjesu doda se kap po kap 5.85 ml (47.6 mmol) pivaloil klorida na -15°C, smjesa se miješa na temperaturi dodatno kroz 1 sat, potom se doda 12.5 ml 25% vodenog amonija i miješa kontinuirano kroz 1 sat. Reakcijska smjesa se kasnije ispere s vodom, 1 N otopinom NaOH i vodom, osuši iznad natrij sulfata: dobije se 5.9 g (88 %) očekivanog produkta kao bezbojno ulje. 1H-NMR (DMSO-d6) : δ 1.39 (s,9H), 3.00 i 3.25 (q,2x1H), 4.32 i 4.57 (q,2x1H), 4.3-4.59 (br,1H), 7.11 i 7.43 (s,2x1H).
d.) (4R) -tiazolidin-4-karboksamid hidroklorid
opće formule (VIII), gdje Z znači skupinu formule (A)
9.25 g (39.8 mmol) tert-butil (4R)-4-(aminokarbonil)tiazo-lidin-3-karboksilata rastopi se u 45 ml 25% etanolne otopine klorovodika i miješa kroz 5 sati. Nastali bijeli kristali se odfiltriraju, isperu s dietil eterom. Prinos: 5.42 g (81 %), t.t.: 216-216°C. 1H-NMR (DMSO-d6) : δ 3.04 i 3.6 (q,2x1H), 4.8(q,2H), 4.8 (q,1H), 7.6 i 8.17 (s,2x1H), 10.09 (širok,2H).
e.) (4R)-3-(2-kloracetil)tiazolidin-4-karboksamid
opće formule (IX), gdje Z znači skupina formule (A)
U suspenziju od 8.83 g (52.3 mmol) (4R)-tiazolidin-4-karboksamid hidroklorida u 180 ml diklormetana 14.7 ml (105 mmol) trietilamina, potom se doda kap po kap 4.4 6 ml (56 mmol) kloracetil klorida u 20 ml diklormetana na 0°C. Smjesa se miješa kroz 30 minuta, ostavi da se zagrije na sobnu temperaturu, i dodatno miješa 2 sata. Nastala smjesa se ekstrahira s 3x200 ml vode, spojene vodene faze se koncentriraju u vakuumu na ~ 1/3 volumena i učine alkalnim s 20% otopinom NaOH. Očekivani produkt se dobije kao bijeli kristale. Prinos: 8.12 g (75%), t.t. : 119-121°C. 1H-NMR (DMSO-d6) : δ 3.05 i 3.23 (q,2x1H), 4.39-4.54 (m, 3H), 4.71 (d,2H), 7.20 i 7.43 (s,2x1H).
f.) (4R) -3- (2-kloracetil) tiazolidin-4-karbonitril
opće formule (III), gdje Z znači skupina formule (A)
7.78 g (37.3 mmol) (4R)-3-(2-kloracetil)tiazolidin-4-karboksamida se suspendira u 65 ml suhog acetonitrila, doda se 3.7 ml suhog dimetilformamida, potom na -10°C, kap po kap 3.51 ml (40.6 mmol) oksalil klorida u 8 ml acetonitrila. Smjesa se miješa kroz 1 sat, i ukapa 6.6 ml suhog piridina. Nakon 1 sat miješanja smjesa se evaporira do suhoga, ostatak se miješa s vodom i ekstarhira s diklormetanom. Spojene organske faze se isperu s 1:1 klorovodične kiseline, potom s vodom. Nakon sušenja i evaporiranja očekivani produkt se kristalizira iz etanola: 3.09 g (43 %).
T.t.: 106-108°C. 1H-NMR (CDC13) : δ 3.33 (d, 2H), 4.14 (s,2H), 4.69 (q,2H), 5.27 (s,1H).
g.) (4R)-3-(2-{[8-(2-pirimidinil)-8-azabiciklo[3.2.1]okt-3-il] ekso-amino}acetil) tiazolidin-4-karbonitril
245 mg (1,2 mmol) 8-(2-pirimidinil)-8-azabiciklo[3.2.1]okt-3-il-ekso-amin i 191 mg (1 mmol) (4R)-3-(2-kloracetil) tiazolidin-4-karbonitrila i 0.42 ml (3 mmol) trietilamina se rastopi u 20 ml suhog acetonitrila i miješa na 70°C kroz 4 sata i potom na sobnoj temperaturi preko noći. Potom se smjesa evaporira da se dobije žuto gusto ulje koje se purificira kolonskom kromatografijom upotrebom kloroform-metanol (9:1) eluenta pa se dobije bijeli produkt koji se kristalizira iz dietil etera. Prinos: 191 mg (53 %). T.t.: 135-136°C. 1H-NMR (400 MHz, DMSO-d6) : δ 1.33 (td,2H), 1.6-2.0 (m, 5H), 3.05 (tt,1H), 3.32 (m,2H), 3.44 (ddd,2H), 4.63 (s,2H), 4.56 (d,1H), 4.61 (m,2H), 4.70 (m,1H), 5.23 (dd,1H), 6.60 (t,1H), 8.33 (n,2H).
Primjer 2.
(4R)-3-(2-{[8-(5-cijanopiridin-2-il)-8-azabiciklo[3.2.1] okt-3-il]-ekso-amino}acetil)tiazolidin-4-karbonitril dihidroklorid
U općoj formuli (I) R stoji za 5-cijanopiridin-2-il skupinu, B označava skupinu formule (1), Z stoji za skupinu formule (A).
a.) tert-butil 8-(5-cijanopiridin-2-il)-8-azabiciklo[3.2.1]okt-3-il-ekso-karbamat
opće formule (V), gdje R i B su kao što je dato gore, Y je tert-butoksikarbonil skupina
Otopina od 415 mg (3 mmol) 2-klor-5-cijanopiridina, 679 mg (3 mmol) tert-butil 8-azabiciklo [3.2 .1] okt-3-il-ekso-karbamata i 0.46 ml (3.1 mmol) diazabiciklo[5.4.0]undecena u 25 ml n-pentanola dovede se do refluksa kroz 8 sati. Nastala otopina se evaporira u vakuumu, ostatak se rastopi u diklormetanu, ispere s vodom i osuši iznad natrij sulfata. Nakon purifikacije kromatografijom koristeći n-heksan-etil acetat-kloroform (2:1.1) kao eluenta dobije se 608 mg (62%) imenovanog materijala. T.t.: 141-143°C. 1H-NMR (DMSO-d6) : δ 1.38 (s,9H), 1.44-1.68 (t,2H), 1.67-2.01 (m,6H), 3.88 (m,1H), 4.60 (bs,2H), 6.61 (d,1H), 6.80 (d,1H), 7.81 (dd,lH), 8.48 (d,1H).
b.) 8- (5-cijanopiridin-2-il) -8-azabiciklo [3.2 .1] okt-3-il-ekso-amin
opće formule (II) - gdje su R i B dati u fazi 2a.
Otopina od 675 mg (2 mmol) tert-butil 8-(cijanopiridin-2-il)-8-azabiciklo [3.2.1]okt-3-il-efcso-karbamata u 20 ml 12% etanolne otopine hidrogen klorida se miješa na sobnoj temperaturi kroz 3 sata. Nastaloj bijeloj suspenziji doda se 20 ml vode da bi se dobila otopina koja se alkalizira na pH >10 s 40% kalij hidroksidom i ekstrahira s diklormetanom. Organska faza se osuši iznad natrij sulfata i evaporira. Ostatak se kristalizira iz n-heksana da bi se dobilo 259 mg (57 %) imenovanog spoja, t. t. : 123-124°C. 1H-NMR (DMSO-d6) : δ 1.26 (t,2H), 1.68-1.93 (m, 6H), 3.12 (m,1H), 4.57 (b,2H), 6.78 (d,1H), 7.79 (dd,1H), 8.46 (d,1H).
c.) (4R)-3-(2-{[8-(5-cijanopiridin-2-il)-8-azabiciklo[3.2.1]oktan-3-il]-ekso-amino)acetil)tiazolidin-4-karbonitril dihidroklorid
114 mg (0.6 mmol) 8-(5-cijanopiridin-2-il)-8-azabiciklo [3.2.1]okt-3-il-ekso-amina i 114 mg (0.8 mmol) (4R)-3-(2-kloracetil)tiazolidin-4-karbonitrila se rastope u 20 ml acetonitrila i otopina se doda u otopinu od 460 mg (1.1 mmol) PBEMP. Smjesa se miješa na 55°C kroz 16 sati, skupljena smola se odfiltrira a filtrat se evaporira. Ostatak se kromatografski purificira koristeći kloroform-metanol (9:1) kao eluent. Nakon acidifikacije s etanolnom otopinom hidrogen klorida i precipitacije s dietil eterom dobije se imenovani spoj u obliku bijelih kristala: 75 mg (32%), t.t.: 204-206°C. 'H-NMR (DMSO-d6) : δ 1.70-1.78 (m,4H), 2.01 (m, 4H), 3.37 (m,2H), 3.67 (m,1H), 4.07 (m,1H), 4.21 (m,1H), 4.56 (d,1H), 4.76-4.79 (m,3H), 5.33 (m,1H), 6.89 (d,1H), 7.91 (dd,1H), 8.53 (d,1H), 9.01 (bs,2H).
Primjer 3.
(4R) -3- (2-{[8- (2-pirazinil)-8-azabiciklo[3.2.1]okt-3-il] ekso-amino}acetil tiazolidin-4-karbonitril dihidroklorid
Značenje R je 2-pirazinil skupina, B znači skupinu formule (1), Z znači skupinu formule (A) u općoj formuli (I).
a.) tert-butil 8-(2-pirazinil)-8-azabiciklo[3.2.1]okt-3-il-ekso-karbamat
opće formule (V) - gdje R i B su dati gore, Y je tert-butoksikarbonil skupina
0.54 ml (6 mmol) klorpirazina, 1.13 g (6 mmol) tert-butil 8-azabiciklo [3.2 .1] okt-3-il-ekso-karbamata i 0.97 ml (6.5 mmol) 1,8-diazabiciklo[5.4.0]undec-7-ena rastopi se u 40 ml n-pentanola i zagrije do refluksa kroz 50 sati. Otapalo se evaporira, ostatak se rastopi i 50 ml kloroforma, ispere s 4x30 ml vode, osuši iznad natrij sulfata, i purificira kolonskom kromatografijom upotrebom n-heksan-etil acetat-kloroform (3:1:1) kao eluenta da bi se dobili bijeli kristali koji se usitne s n-heksanom. Prinos: 0.55 g (36%). T.t.: 122-123°C. 1H-NMR (DMSO-d6) : δ 1.34 (s, 9H), 1.44-1.66 (m, 2H), 1.67-1.99 (m,6H), 3.88 (m,1H), 4.56 (bs,2H), 6.59 (d,1H), 7.77 (d,1H), 8.07 (dd,1H), 8.17 (d,1H).
b.) 8- (2-pirazinil) -8-azabiciklo [3 .2.1] okt-3-il-ekso-amin
opće formule (II) - gdje R i B su dati u fazi 3a.)
3.84 g (1.26 mmol) tert-butil 8-(2-pirazinil)-8-azabiciklo[3.2.1] okt-3-il-ekso-karbamata rastopi se u 20 ml 12% etanolne otopine klorovodične kiseline i otopina se miješa kroz 7 sati. Potom se doda 20 ml vode da bi nastala suspenzija, a pH se dovede na 11 s vodenim kalij hidroksidom. Slojevi se odvoje, organske faze se osuše, evaporiraju i purificiraju kolonskom kromatografijom upotrebom etil acetat-metanol-25 % vodena otopina amonija (17:3:1) kao eluent da bi se dobilo svijetlo žuto ulje. Prinos je 167 mg (65 %). lH-NMR (DMSO-d6) : δ 1.29 (t,2H), 1.62-1.83 (m,4H), 1.84-2.00 (m,2H), 3.12 (S,1H), 4.57 (dd,2H), 7.74 (d,1H), 8.05 (dd,1H), 8.15 (d,1H).
c.) (4R)-3- (2-{[8-(2-pirazinil)-8-azabiciklo[3.2.l]okt-3-il] ekso-amino}acetil) tiazolidin-4-karbonitril dihidroklorid
107 mg (0.52 mmol) 8-(2-pirazinil)-8-azabiciklo[3.2.1]okt-3-il-efcso-amina i 86 mg (0.45 mmol) (4R)-3-(2-kloracetil)tiazolidin-4-karbonitrila rastopi se u 15 ml acetonitrila i u otopinu se doda 0.21 ml (1.5 mmol) trietilamina. Smjesa se miješa kroz 4 sata na 75°C potom evaporira u vakuumu. Ostatak se kromatografski purificira upotrebom kloroform-metanol (6:1) kao eluenta. Nakon acidifikacije s etanolnom otopinom hidrogen klorida i precipitacije s dietil eterom, dobio se je imenovani spoj u obliku bijelih kristala: 37 mg (19 %), t.t.: 165-170°C. 1H-NMR (DMSO-d6) : δ 1.76-1.80 (m, 4H), 1.95-2.01 (m, 4H), 3.35 (m, 2H), 3.63 (m,1H), 4.05 (m,1H), 4.18 (m,1H), 4.57 (d,1H), 4.67 (s,2H), 4.78 (d,1H), 5.32 (dd,1H), 7.87 (d,1H), 8.15 (dd,1H), 8.28 (d,1H), 8.99 (bs,2H).
Primjer 4
(2S)-1-(2-{[8-(5-nitropiridin-2-il)-8-azabiciklo[3.2.l]oktan-3-il]-ekso-amino}acetil)pirolidin-2-karbonitril
Značenje R je 5-nitropiridin-2-il skupina, B označava skupinu formule (1), Z znači skupinu formule (B) u općoj formuli (I).
a.) tert-butil 8-(5-nitropiridin-2-il)-8-azabiciklo[3.2.1]okt-3-il-ekso-karbamat
opće formule (V), gdje R i B su dati gore, Y je tert-butoksikarbonil skupina
476 mg (3-mmol) 2-klor-5-nitropiridina, 679 mg (3 mmol) tert-butil 8-azabiciklo [3. 2. l]okt-3-il-ekso-karbamata i 0.46 ml (3.1 mmol) 1,8-diazabiciklo[5.4.0]undec-7-ena se rastopi u 25 ml n-pentanola i zagrije do refluksa kroz 1 h. Otapalo se evaporira, ostatak se rastopi u 40 ml kloroforma, ispere s 4x40 ml vode, osuši iznad natrij sulfata i evaporira. Čvrsti ostatak se usitni s dietil eterom da bi se dobili žuti kristali. Prinos 731 mg (70 %). T.t.: 212-214°C. 1H-NMR (DMSO-d6) : δ 1.34 (s,9H), 1.41-1.54 (m,2H), 1.81-2.16 (m,6H), 4.00 (m,1H), 4.75 (bs,2H), 6.63 (d,1H), 6.82 (d,1H), 8.21 (dd,1H), 8.98 (d,1H).
b.) 8-(5-nitropiridin-2-il)-8-azabiciklo[3.2.1]okt-3-il-ekso-amin
opće formule (II), gdje su R i B dati u fazi 4a.)
651 mg tert-butil 8-(5-nitropiridin-2-il)-8-azabiciklo [3.2.1] okt-3-il-ekso-karbamata (1.87 mmol) se rastopi u 20 ml 12 % etanolne klorovodične kiseline i otopina se miješa kroz 3 sata. Uz hlađenje doda se 90 ml 1N natrij hidroksida u nastalu suspenziju koja se ekstrahira s 4 x 50 ml diklormetana. Slojevi se odvoje, organske faze se osuše, evaporiraju a ostatak se usitni s n-heksanom da bi se dobili žuti kristali.
Prinos je 426 mg (92 %). T.t.: 175-178°C. 1H-NMR (200 MHz, DMSO-d6) : δ 1.29 (t,2H), 1.68-1.98 (m,6H), 3.17 (m, 1H), 4.64 (dd,2H), 6.44 (d,1H), 8.12 (dd,1H), 8.95 (d,1H).
c.) (2S)-1-(2-{[8-(5-nitropiridin-2-il)-8-azabiciklo[3.2.1] oktan-3-il] -ekso-amino}acetil) pirolidin-2-karbonitril
112 mg (0.45 mmol) 8-(5-nitropiridin-2-il)-8-azabiciklo [3.2.1]okt-3-il-ekso-amin reagira s 103 mg (0.54 mmol) (2S)-1-(2-kloracetil)pirolidin-2-karbonitrila (J.Med.Chem 2002, 45, 2362) u prisutnosti 450 mg (1.13 mmol) PBEMP u 20 ml acetonitrila, kao što je opisano u Primjeru 2c). Nakon završene reakcije i kormatografske purifikacije (kloroform-metanol 9:1) produkt se kristalizira iz etil acetata: 75 mg (41 %). T.t.: 177-179°C. lH-NMR (DMSO-d6) : δ 1.34 (t,2H), 1.88 (m,3H), 1.93-2.01 (m,6H), 2.11 (m,2H), 3.07 (m,1H), 3.32 (m,1H), 3.38 (m,1H), 3.55 (m,1H), 4.50 (b,lH), 4.71 (m,1H), 4.92 (b,1H), 8.20 (dd,1H), 8.97 (d,1H).
Primjer 5
(4S)-3-(2-{[8-(pirimidin-2-il)-8-azabiciklo[3.2.l]okt-3-il]ekso-amino}acetil-l,3-oksazolidin-4-karbonitril
Značenje R je pirimidin-2-il skupina, B znači skupinu formule (1), Z znači skupinu formule (C) u općoj formuli (I).
a.) tert-butil (4S) -4- (aminokarbonil) -1, 3-oksazolidin-3-karboksilat
opće formule (VII), gdje Z znači skupinu formule (C)
15.8 g (73 mmol) (4S)-3-(tert-butoksikarbonil)-1,3-oksazolidin-4-karboksilna kisleina (Tetrahedron, 1994, 50, 13493) se rastopi u 100 ml diklormetana i doda u otopinu 8 ml (73 mmol) 4-metilmorfolina. U nastalu smjesu doda se kap po kap, na -15°C 7 ml (73 mmol) etil klorformata i smjesa se miješa na toj temperaturi kroz 1 sat, potom se ukapa 30 ml 25 % vodene otopine amonija i smjesa se miješa kroz 1 sat. Reakcijska smjesa se ispere s vodom, 1N otopinom NaOH, potom s vodom, osuši iznad natrij sulfata i evaporira. Dodavanjem 9.10 g (58 %) dietil etera gore navedeni produkt kristalizira. T.t.: 95-96°C. 1H-NMR (CDCl3) : δ 1.49 (s,9H), 4.13 (m,1H), 4.37 (m,2H), 4.80 (d,1H), 4,98 (d,1H), 5.67 (bs,1H), 6.58 (bs,1H).
b.) (4S)-1,3-oksazolidin-4-karboksamid hidroklorid
opće formule (VIII), gdje Z znači skupinu formule (C)
5.4 g (15.7 mmol) tert-butil (4S)-4-(aminokarbonil)1,3-oksazolidin-3-karboksilat rastopi se u 25 ml 25 % etanolne otopine hidrogen klorida i miješa na sobnoj temperaturi kroz 4 sata. U nastalu suspenziju doda se 150 ml dietil etera, nastali bijeli kristalni materijal se odfiltrira. Dobije se 3,74 g (98%) gore navedenog produkta.
T.t.: 155-158 °C. 1H-NMR (DMSO-d6) : δ 4.00 (m,1H), 4.21-4.39 (m, 2H), 4.68 (d,1H), 4.77 (d,1H), 7.82 (s,1H), 8.1-7 (s,1H), 10.12 (br,2H).
c.) (4S)-3-(2-kloracetil)-1,3-oksazolidin-4-karboksamid
opće formule (IX), gdje Z znači formulu (C)
2.82 g (18 mmol) (4S)-1,3-oksazolidin-4-karboksamid hidroklorida se suspendira u 50 ml diklormetana i u tu suspenziju se doda 5,6 ml (40 mmol) trietilamina. U nastalu smjesu se ukapa, ispod -10°C 1.60 ml (20 mmol) kloracetil klorida u 20 ml diklormetana. Nakon 2 sata miješanja suspenzija se prelije u 500 ml etil acetata, precipitirani trietilamin hidroklorid se odfiltrira, filtrat se evaporira a ostatak se kristalizira iz diklormetana. Dobije se 2.30 g (65 i) gore navedenog produkta u obliku bež kristala. T.t.: 131-133°C. 1H-NMR (DMSO-d6) : δ 3.91 (m,1H), 4.06-4.16 (m,2H), 4.20-4.40 (m,2H), 5.00 (q,2H), 7.20 i 7.45 (s,2x1H).
d.) (4S)-3-(2-kloracetil)-1,3-oksazolidin-4-karbonitril
opće formule (III), gdje Z znači skupinu formule (C)
2.12 g (11 mmol) (4S)-3-(2-kloracetil)-1,3-oksazolidin-4-karboksamida se rastopi u 200 ml dikoormetana i 20 ml acetonitrila potom se uz to doda 2.62 ml (28 mmol) fosfornog oksiklorida. Smjesa se zagrije kroz 24 sata (ako preostane početnog materijala on se dovede do refluksa). Tijekom refluksa otopina postane crvena i precipitira u ljepljivi kruti materijal. Otopina se dekantira i doda se 50 g kalij karbonata. Nakon miješanja kroz sat vremena odfiltrira se krute soli a otopina se evaporira. Dobiveno crveno ulje se purificira kolonskom kromatografijom (diklormetan-metanol 9:1). Sakupe se bijeli kristali i usitne s dietil eterom. Prinos: 1.1 g (53 %). T.t.: 99-100 °C. 1H-NMR (CDCl3) : δ 3.88-4.10 (m,2H), 4.10-4.32 (m,2H), 4.76 (m,1H), 5.08 (q,2H).
e.) (4S) -3- (2-{[8-(pirimidin-2-il)-8-azabiciklo[3.2.1]okt-3-il] ekso-amino}acetil) -1, 3-oksazolidin-4-karbonitril
245 mg (1.2 mmol) 8- (2-pirimidinil)-8-azabiciklo[3.2.1]-okt-3-il-ekso-amina i 175 mg (1 mmol) (4S)-3-(2-kloracetil)-1,3-oksazolidin-4-karbonitrila i 0.42 ml (3 mmol) trietilamina se rastopi u 20 ml suhog acetonitrila i miješa na 70°C kroz 4 sata i potom na sobnoj temperaturi preko noći. Smjesa se zatim evaporira da se dobije žuto ljepljivo ulje koje se purificira kolonskom kromatografijom upotrebom diklormetan-metanol (9:1) kao eluenta a dobije se čvrsti bijeli produkt koji se kristalizira iz dietil etera. Prinos: 248 mg (73 %). T.t.: 122-125°C. 1H-NMR (CDCl3) : δ 1.60 (td,2H), 1.72-1.92 (m, 4H), 2.07 (t,2H), 3.13 (m,1H), 3.37 (s,2H), 3.49 (s,1H), 3.55 (b,1H), 4.80 (m,3H), 5.03 (d,1H), 6.52 (t,1H), 8.32 (dd,2H).
Primjer 6
(2S)-1-(2-{[8-(5-cijanopiridin-2-il)-8-azabiciklo[3.2.1]okt-3-il] ekso-amoino}acetil)-2,5-dihidro-1H-pirole-2-karbonitril dihidroklorid
Značenje R je 5-cijanopiridin-2-il skupina, B-znači skupinu formule (1), Z znači skupinu formule (D) u općoj formuli (I).
a.) tert-butil (2S)-2-(aminokarbonil)-2,5-dihidro-1H-pirol-1-karboksilat
opće formule (VII), gdje Z znači skupinu formule (D)
U otopinu od 4.04 g (18.9 mmol) (2S)-2,5-dihidro-1H-pirol-2-karboksilne kiseline {J.Org.Chem. 1994, 59, 5192) i 60 ml diklormetana doda se 2.9 ml (21 mmol) trietilamina. Pivaloil klorid (2.4 ml, 2 0 mmol) i 9 ml diklormetana se doda kap po kap na -5°C i smjesa se miješa na toj temperaturi kroz 1 sat i potom se doda 9.5 ml 25 % vodene otopine amonija i smjesa se miješa 4 sata. Reakcijska smejsa se ispere s 3x100 ml vode. Spojeni vodeni spoj se ekstrahira s 7x50 ml diklormetana. Spojeni organski sloj se osuši iznad natrij sulfata i evaporira. Uljni produkt se polako kristalizira. Dobije se 3.09 g (77%) gore navedenog produkta. T.t.: 127-133°C. 1H-NMR (DMSO-d6) : δ 1.36 (s,9H), 4.07 (m,2H), 4.70 (m,1H), 5.70 (m,lH), 5.95 (m,1H), 6.99 (br, 1H), 7.38 (br, 1H).
b.) (2S)-2.5-dihidro-1H-pirol-2-karboksamid klorid
opće formule (VIII), gdje Z znači skupina formule (D)
6.27 g (29.5 mmol) tert-butil (25)-2-(aminokarbonil)-2,5-dihidro-1H-pirol-1-karboksilat se rastopi u 170 ml 25 % etanolne otopine hidrogen klorida i miješa na sobnoj temperaturi kroz 6.5 sati. U nastalu suspenziju doda se dietil eter (300 ml), nastali bijeli kristalni materijal se odfiltrira. Dobije se 2.98 g (70%) gore navedenog produkta. T.t.: 181-184°C. 1H-NMR (DMS0-d6) : δ 4.00 (m,2H), 4.94 (s,1H), 5.97 (s,2H), 7.77 (S,1H), 8.29 (s,1H), 8.71 (br, 1H), 10.87 (br,1H).
C.) (2S)-1-(2-kloracetil)-2,5-dihidro-1H-pirol-2-karboksamid
opće formule (IX), gdje Z znači skupinu formule (D)
U otopinu od 0.44 g (3 mmol) (2S)-2,5-dihidro-1H-pirol-2-karboksamid hidroklorida u 20 ml diklormetana doda se 4.1 (2 9.3 mmol) trietilamina na temperaturi ispod -5 °C. U tu smjesu doda se kap po kap otopina od 0.66 g (6.5 mmol) kloracetil klorida u 10 ml diklormetana. Nakon miješanja kroz 30 minuta na -5°C i 3 sata na sobnoj temperaturi suspenzija se evaporira. Ostatak se suspendira u 50 ml etil acetata, odfiltrira i ispere s etil acetatom. Filtrat se evaporira a ostatak se kromatografira u diklormetan-metanol (40:1 D 10:1) kao eluentom. Dobije se 0.26 g (46 %) gore navedenog produkta kao bezbojno ulje.
1H-NMR (DMSO-d6) : δ 4.32 (m,2H), 4.37 (q,2H), 4.85 (m,veliki) i 5.12 (m,mali) (IH), 5.83 (m,1H), 6.02 (m,1H), 7.01 (br, veliki) i 7.33 (br,mali) (IH), 7.38 (br,veliki) i 7.69 (br,mali) (1H).
d.) (25) -1- (2-kloracetil) -2, 5-dihidro-1H-pirol-2-karbonitril
opće formule (III), gdje Z znači skupinu formule (D)
U otopinu od 0.25 g (1.32 mmol) (2S)-1-(2-kloracetil)-2,5-dihidro-1H-pirol-2-karboksamida u 8 ml acetonitrila i 0.15 ml dimetil-formamida doda se kap po kap na -5°C 0.13 ml (1.45 mmol) fosfornog oksiklorida u 2 ml acetonitrila. Smjesa se miješa na sobnoj temperaturi kroz 4 sata i potom se razrijedi s 50 ml diklormetana i ispere s vodom i vodenom otopinom hidrogen karbonata, osuši i evaporira. Ostatak se kromtografski purificira u diklormetan-metanol (100:1) kao eluentu. Prinos: 84 mg (37 %), bezbojno ulje. 1H-NMR (CDCl3) : δ 4.08 (s,2H), 4.48 (m, 2H), 5.40 i 5.60 (m,1H), 5.86 (m,mali) i 5.92 (m.veliki)(IH), 6.15 (m,veliki) i 6.24 (m,mali)(1H).
e.) (25) -1- (2-{[8-(5-cijanopiridin-2-il)-8-azabiciklo[3.2.1] okt-3-il]ekso-amino}acetil) -2, 5-dihidro-1H-pirol-2-karbonitril dihidroklorid
U otopinu od 0.25 g (1,1-mmol) 8-(5-cijanopiridin-2-il)-8-azabiciklo [3.2.1] okt-3-il-e.fcso-amina i 0.16 ml (1.2 mmol) trietilamina u 10 ml acetonitrila doda se 0.17 g (1 mmol) (2S)-1-(2-kloracetil)-2, 5-dihidro-1H-pirol-2-karbonitrila i reakcijska otopina se miješa na 70°C kroz 3 sata. Reakcijska smjesa se evaporira a ostatak se rastopi u 50 ml diklormetana i potom ispere s vodom, osuši i evaporira. Ostatak se kromatografski purificira upotrebom CH2Cl2-Me0H (10:1) smjesom kao eluentom. Nakon acidifikacije s otopinom hidrogen klorida i precipitacije s dietil eterom, imenovani spoj se dobije u obliku bijelih kristala: 174 mg (39 %) ; t.t.: 305-9°C. 1H-NMR (DMSO-d6) : δ 1.76 (m,4H), 1.99 (m,4H), 4.05 (t,2H), 4.39 (m,2H), 4.71 (br, 1H), 5.56 (m,1H), 6.00 (m,1H), 6.28 (m,1H), 6.90 (d,1H), 7.92 (dd,1H), 8.55(d,1H), 9.00 (br,2H).
Primjer 7
(2S,4R)-4-hidroksi-1-(2-{[8-(pirimidin-2-il)-8-azabiciklo[3.2.1]okt-3-il]ekso-amino}acetil)pirolidin-2-karbonitril dihidroklorid
Značenje R je pirimidin-2-il skupina, B znači skupinu formule (1), Z znači skupinu formule (E) u općoj formuli (I).
a.) tert-butil (2S,4R)-2-(aminokarbonil)-4-hidroksipirolidin-1-karboksilat
opće formule (VII), gdje Z znači skupinu formule (E)
36.32 g (157 mmol) (2S, 4R) -1- (tert-butilkarbonil) -4-hidroksi-pirolidin-2-karboksilna kiselina (Aldrich) se rastopi u 450 ml tetrahidro-furana i u otopinu se doda 24 ml (172 mmol) trietilamina. U nastalu smjesu, na -10°C doda se kap po kap 16.3 ml (172 mmol) etil klorformata i na istoj temperaturi se miješa kroz 1 sat. Čuva se na temperaturi ispod -5°C, 110 ml 25 % vodene otopine amonija se doda kap po kap i smjesa se miješa kroz 2 sata na sobnoj temperaturi. Reakcijska smjesa se prelije u 270 ml zasićene otopine amonij klorida. Nakon odvajanja vodenog sloja odvoji se s 2x 50 ml tetrahidrofurana. Spojena organska otopina se osuši iznad natrij sulfata i evaporira. Nakon dodavanja 21,19 g (59 %) dietil etera kristalizira se gore navedeni produkt. T.t.: 130-132 °C. (MH+)= 231.
b.) (25, 4R)-1-(2-kloracetil)-4-hidroksipirolidon-2-karbonitril
opće formule (III), gdje Z znači skupina formule (E)
(25,4R)-1-(tert-butoksikarbonil)-4-hidroksipirolidin-2-karbonitril
7.82 g (34 mmol) tert-butil (2S, 4R)-2-(aminokarbonil)-4-hidroksipirolidin-1-karboksilat se arstopi u 80 ml piridina i 12 ml (84 mmol) trifluoroctenog anhidrida se doda u otopinu kap po kap -20°C. Smjesa se miješa jedan dan na sobnoj temperaturi. Višak anhidrida se hidrolizira dodavanjem nekoliko kapi vode. U tu smjesu se doda 200 ml etil acetata i ispere se s 10% vodenom otopinom hidrogen klorida (na pH 3-5), 50 ml 2N otopinom natrij hidroksida u 50 ml slane otopine. Organska otopina se osuši iznad natrij sulfata i evaporira da bi se dobilo ulje. Prinos 5.34 g (74 %). (MH+)= 213, (MH+)2= 426.
(2S,4R)-4-hidroksipirolidin-2-karbonitril-4-metilbenzen sulfonat
6.40 g (30 mmol) (2S, 4R)-1-(tert-butoksikarbonil)-4-hidroksi-pirolidin-2-karbonitril se rastopi u 100 ml acetonitrila i doda se u otopinu 8.56 g (45 mmol) monohidrata 4-metilbnezensulfonske kiseline. Smjesa se miješa na sobnoj temperaturi kroz 24 sata i evaporira se pod reduciranim tlakom. Doda se 500 ml dietil etera u nastalo smeđe ulje. Miješa se 10 minuta i čuva se u hladnjaku preko noći. Nastali bijeli kristalni materijal se odfiltrira i ispere s dietil eterom. Dobije se 6.31 g (73 %) gore navedenog produkta. T.t.: 110-113°C.
(2S,4R)-1-(2-kloracetil)-4-hidroksipirolidin-2-karbonitril
6.31 d (22 mmol) (2S,4R)-4-hidroksipirolidin-2-karbonitril-4-metilbenzensulfonata se suspendira u 37 ml diklormetana i u to se doda 37 ml diklormetana i 4.1 ml (48 mmol) trietilamina. Smjesu se čuva na temperaturi ispod -10°C, i u to se doda kap po kap 2,1 ml (26 mmol) kloracetil klorida u 28 ml diklormetana. Nakon 2 sata miješanja suspenzija se prelije u 450 ml etilacetata, precipitat se odfiltrira, filtrat se evaporira i purificira kolonskom kromatografijom upotrebom linearnog gradijenta metanola u diklormatanu (0 o 20 % v/v) kao eluenta. Dobije se 3.51 g (84 %) gore navedenog produkta u obliku bezbojnog ulja. (MH+)=189.
c.) (25, 4R)-4-hidroksi-1-(2-{[8-(pirimidin-2-il)-8-azabiciklo [3.2.1]okt-3-il]ekso-amino}acetil)pirolidin-2-karbonitril
204 mg (1 mmol) 8-(2-pirimidinil)-8-azabiciklo[3.2.1]okt-3-il-ekso-amina, 189 mg (1 mmol) (2S, 4R)-1-(2-kloracetil)-4-hidroksipirolidin-2-karbonitrila i 0.25 ml (1.8 mmol) trietilamina se rastopi u 15 ml suhog acetonitrila i miješa na 70°C kroz 5 sati i potom na sobnoj temperaturi preko noći. Acetonitril se odstarni pod reduciranim tlakom a ostatak se rastopi u 15 ml diklormetana i 15 ml slane otopine. Nakon odvajanja vodeni sloj se ispere s diklormetanom, a spojeni organski sloj se osuši i evaporira. Nastalo smeđe ulje se purificira kolonskom kromatografijom upotrebom linearnog gradijenta metanol i diklormatan (0 □ 20 % v/v) kao eluenta. Evaporirani produkt se tretira s n-heksanom. Prinos: 133 mg (38 %). T.t.: 165-167°C, (MH+)=357. 1H-NMR (DMSO-d6) : δ 1.35 (td,2H), 1.6-2.0 (m,7H), 2.20 (dd,2H), 3.02 (m,1H), 3.3-3.6 (m,2H), 3.61 (dd,lH), 4.35 (dd,1H), 4.61-4.67 (m,3H), 5.30 (d,1H), 6.60 (t,1H), 8.34(m,2H).
Primjer 8
(2S)-4-okso-1-(2-{[8-(pirimidin-2-il)-8-azabiciklo[3.2.1]okt-3-il]ekso-amino}acetil)pirolidin-2-karbonitril dihidroklorid
Značenje R je pirimidin-2-il skupina, B znači skupinu formule (1), Z znači skupinu formule (F) u općoj formuli (I).
357 mg (1 mmol) (2S, 4R) -4-hidroksi-1-(2-{[8-(pirimidin-2-il)-8-azabiciklo [3.2.1] okt-3-il] ekso-amino}acetil) pirolidin-2-karbonitrila se rastopi u 20 ml acetona. Na temperaturi ispod 0°C doda se uz miješanje kap po kap 1.25 ml 8N otopina Jones-ovog reagensa. Smjesa se miješa 16 sati na istoj temperaturi. Otopina se dekantira a ljepljiva crna krutina se ispere s 2x25 ml acetona. Zasićena otopina kalij karbonata se doda da spojena otopina acetona bude pH 10. Aceton se odstrani a ostatak se ekstrahira s 3x20 ml etil acetata. Spojeni ekstrakti se isperu s 15 ml slane otopine, osuše iznad natrij sulfata i evaporiraju. Smeđe ulje se purificira kolonskom kromatografijom upotrebom linearnog gradijenta metanol u diklormetanu (0 □ 50% v/v) kao eluenta. Evaporirani produkt je žuto ulje. Prinos: 77 mg (22 %). (MH+) =355
Slijedeći postupke, navedene za Primjere 1-8, spojevi nabrojani u Tablici 1 su proizvedeni kao slobodne baze ili kao soli.
[image]
[image]
[image]
[image]
Slijedeći postupke, navedene za Primjere la), 2a), 3a) i 4a), proizvedeni su spojevi V nabrojani u Tablici 2.
[image]
[image]
[image]
Slijedeći postupke, navedene za Primjere lb), 2b), 3b) i 4b), proizvedeni su spojevi II nabrojani u Tablici 3.
[image]
[image]
[image]
Claims (20)
1. Spojevi opće formule (I) naznačeni time, da R znači
- aromatski dio s jednim ili dva prstena koji sadržavaju dušik, preferirano piridil, piridazinil, pirimidinil, pirazinil, imidazolil, pirazolil, tiazolil, izotiazolil, oksazolil, izoksazolil, oksadiazolil, kvinolinil, izokvinolinil, cinolilnil, ftalazinil, kvinazolinil, kvinoksalinil, benzimidazolil, indazolil, benzotiazolil, benzisotiazolil, benzoksazolil ili benzisoksazolil dio koji je po izboru mono- ili disubstituiran neovisno s jednom ili dvije od slijedećih skupina: C1-4 alkil skupinom, C1-4 alkoksi skupinom, atomom halogena, atom halogena, trihalogenmetil skupinom, metiltio skupinom, nitro skupinom, cijano skupinom, C2-5 alkoksikarbonil skupinom ili karboksamino skupinom, ili
- p-tolilsulfonil skupina, ili
- R1a-CH2-skupina, gdje je značenje Rla vodik, C1-4 alkil skupina, fenil, benzil, feniletil, naftil, piridil, kvinolil, izokvinolil, cinolinil, ftalazinil, kvinazolinil, kvinoksalinil, tienil, furil ili p-toluensulfonil dio nezavisno substituiran s jednom ili više C1-4 alkil skupina, C1-4 alkoksi skupinom, alkilendioksi skupinom, atomom halogena, trihalogenmetil, nitro ili cijano skupinom, ili
- R1b-CO-skupina, gdje je značenje R1b C1-4 alkil skupina, fenil, benzil, feniletil, feniletenil, naftil, piridil, kvinolil, izokvinolil, cinolinil, ftalazinil, kvinazolinil ili kvinaksalinil dio substituiran nezavisno s jednom ili više C1-4 alkil skupina, C1-4 alkoksi skupina, alkilendioksi skupinom, atomom halogena, trihalogenmetil, nitro ili cijano skupinom, mono- ili disupstituiran amino skupinom, zasićenim heterocikličnim dijelom koji sadržava N, preferirano sa skupinom koja sadržava pirolidino, piperidino, piperazino ili morfolino prsten;
B stoji za skupinu u skladu s formulom (1) ili (2) ili (3) ili (4);
Z stoji za skupine formule (A) ili (B) ili (C) ili (D) ili (E) ili (F); i njihove soli, izomere, tautomere, hidrate ili solvate.
2. Spojevi opće formule (I) kao što je definirano u zahtjevu 1, naznačeni time, da R znači
- aromatski dio s jednim ili dva prstena koji sadržavaju dušik, preferirano piridil, piridazinil, pirimidinil, pirazinil, imidazolil, pirazolil, tiazolil, izotiazolil, oksazolil, izoksazolil, oksadiazolil, kvinolinil, izokvinolinil, cinolinil, ftalazinil, kvinazolinil, kvinoksalinil, benzimidazolil, indazolil, benzotiazolil, benzisotiazolil, benzoksazolil ili benzisokksazolil dio koji je nezavisno jedan od drugog mono- ili disubstituiran s jednom ili dvije od slijedećih skupina: C1-4 alkil skupinom, C1-4 alkoksi skupinom, atomom halogena, trihalogenmetil skupinom, metiltio skupinom, nitroskupinom, cijano skupinom, ili
- p-tolilsulfonil skupina, ili
- R1a-CH2-skupina, gdje je značenje R1a vodik, C1-4 alkil skupina, fenil, benzil, feniletil, naftil, piridil, kvinolil, izokvinolil, cinolinil, ftalazinil, kvinazolinil, tienil, furil ili p-tolilsulfonil dio nezavisno jedan od drugog substituiran s jednom ili više C1-4 alkil skupina, C1-4 alkoksi skupinom, alkilendioksi skupinom, atomom halogena, trihalogenmetil, nitro ili cijano skupinom, ili
- R1b-CO-skupina, gdje je značenje R1b C1-4 alkil skupina, fenil, benzil, feniletil, feniletenil, naftil, piridil, kvinolil, izokvinolil, cinolinil, ftalazinil, kvinazolinil ili kvinaksalinil dio substituiran nezavisno jedan od drugog s jednom ili više C1-4 alkil skupina, C1-4 alkoksi skupina, alkilendioksi skupinom, atomom halogena, trihalogenmetil, nitro ili cijano skupinom, mono- ili disubstituiran amino skupinom, zasićenim heterocikličnim dijelom koji sadržava N, preferirano sa skupinom koja sadržava pirolidino, piperidino, piperazino ili morfolino prsten;
B stoji za skupinu u skladu s formulom (1) ili (2) ili (3) ili (4);
Z stoji za skupine formule (A) ili (B) ili (C) ili (D) ili (E) ili (F); i njihove soli, izomere, tautomere, hidrate ili solvate.
3. Spojeve opće formule (I) kao što je definirano u zahtjevu 1, naznačeni time, da
- R znači pirimidinil-, piridinil-, pirazinil-, piridazinil-, benzotiazolil-, benzisotiazolil-, benzoksazolil-, benzisoksazolil-skupina, koja je u navedenom slučaju neovisno jedna o drugoj mono-ili disubstituirana s jednom ili dvije od slijedećih skupina: C1-4 alkil skupinom, C1-4 alkoksi skupinom, atomom halogena, nitro skupinom, cijano skupinom, C2-5 alkoksikarbonil skupinom ili karboksamino skupinom; ili p-tolilsulfonil skupina; ili
- R1a-CH2-skupina, gdje je značenje Rla benzil skupina ili feniletil skupina substituirana u navedenom slučaju nezavisno s jednom ili više C1-4 alkil pr alkilen dioksi skupinom; ili
- R1b-CO-skupina, gdje je značenje R1b, fenil, benzil, feniletil, feniletenil ili piperidino skupina koja je u navedenom slučaju substituirana neovisno jedna od druge alkilendioksi skupinom;
B stoji za skupinu s formulom (1) ili (2) ili (3) ili (4);
Z stoji za skupine formule (A) ili formule (B) ; i njihove
soli, izomere, tautomere, hidrate ili solvate.
4. Spojevi opće formule (I) kao što je definirano u zahtjevu 1, naznačeni time, da
- R znači pirimidinil-, piridinil-, pirazinil-, piridazinil-, benzotiazolil-, benzisotiazolil-, benzoksazolil, benzisoksazolil-skupinu koja je u navedenom slučaju neovisno jedna od druge mono- ili disubstituirana s jednom ili dvije od slijedećih skupina: C1-4 alkil skupinom, C1-4 alkoksi skupinom, atomom halogena, nitro skupinom, cijano skupinom; ili
- p-tolilsulfonil skupina, ili
- Rla-CH2-skupina, gdje je značenje R1a benzil skupina ili feniletil skupina, neovisno substituirana u navedenom slučaju s jednom ili više C1-4 alkil skupina pr alkilen dioksi skupinom; ili
- R1bCO skupina, gdje je značenje R1b fenil, benzil, feniletil, feniletenil ili piperidino skupina koja je u navedenom slučaju neovisno jedna o drugoj alkilendioksi skupina;
B stoji za skupinu formule (1) ili (2) ili (3) ili (4) ;
Z stoji za skupinu formule (A) ili (B) ; - i njihove soli,
izomere, tautomere, hidrate ili solvate.
5. Spojevi opće formule (I) kao što je definirano u zahtjevu 1, naznačeno -time, da R znači pirimidil ili piridil ili pirazinil skupinu s nitro ili cijano skupinom, B znači skupine formule (1) ili (2), i Z znači skupinu formule (A) ili (B) -kao i njihove, soli, izomere, tautomere, hidrate ili solvate.
6. Zahtjev naznačen time, da je
(4R)-3-(2-{[8-(2-pirimidinil) -8-azabiciklo[3.2.1]okt-3-il]ekso-amino}acetil)tiazolidin-4-karbonitri1;
7. Zahtjev naznačen time, da je
(4R) -3- (2-{ [8- (5-cijanopiridin-2-il) -8-azabiciklo [3.2.l]oktan-3-il]ekso-amino}acetil)tiazolidin-4-karbonitril;
8. Zahtjev naznačen time, da je
(4R)-3-(2-{[8- (5-cijanopiridin-2-il) -8-azabiciklo [3.2.1]oktan-3-il]endo-amino}acetil)tiazolidin-4-karbonitril;
9. Zahtjev naznačen time, da je
(4R) -3- (2-{[8- (2-pirazinil) -8-azabiciklo [3.2.1] okt-3-il] ekso-amino}acetil)tiazolidin-4-karbonitril;
10. Zahtjev naznačen time, da je
(4S)-1-(2-{[8-(5-nitropiridin-2-il) -8-azabiciklo[3.2.1]oktan-3-il]ekso-amino}acetil)pirolidin-2-karbonitril ;
11. Farmaceutski sastav, naznačen time, da sadržava spoj opće formule (I) gdje značenje R, B i Z je isto kao što je definirano u Zahtjevu 1, ili njihove izomere ili solvate, u obliku slobodnog spoja ili soli, i najmanje jedan farmaceutski prihvatljiv pomoćni materijal ili diluente.
12. Postupak proizvodnje spojeva opće formule (I) - gdje značenje R, B i Z je isto kao što je naznačeno u Zahtjevu 1, naznačen time, da reagira sa spojem opće formule (II) gdje je značenje R definirano gore sa spojem opće formule (III) gdje značenje Z je definirano gore i izolacija nastalog spoja opće formule (I) ili njegove soli iz reakcijske smjese.
13. Upotreba spoja opće formule (I) gdje je značenje R, B i Z kao što je definirano u Zahtjevu 1, naznačena time, da su za proizvedeni farmaceutski sastavi prikladni za inhibiciju DPP-IV enzimskog djelovanja, tako da su odgovarajući za tretiranje bolesti povezanih s koncentracijom DPP-IV enzima.
14. Proces inhibicije DPP-IV enzima i tretiranja bolesti povezanih s koncentracijom DPP-IV enzima, naznačen time, da se spoj opće formule (I) kao što je definirano u Zahtjevu 1, primjenjuje u terapijski učinkovitoj količini, u obliku slobodnog spoja, ili soli.
15. Spojevi opće formule (II), naznačeni time, da je značenje R i B kao što je definirano i Zahtjevu 1-i njihove soli.
16. Spojevi opće formule (V), naznačeni time, da je značenje R kao što je definirano u Zahtjevu 1 a Y znači tert-butilkarbonil skupina.
17. Spojevi opće formule (VII), naznačeni time, da je značenje Z kao što je definirano u Zahtjevu 1.
18. Spojevi opće formule (VIII), naznačeni time, da je značenje Z kao što je definirano u Zahtjevu 1, i njihove soli.
19. Spojevi opće formule (IX), naznačeni time, da je značenje Z kao što je definirano u Zahtjevu 1.
20. Spojevi opće formule (III), naznačeni time, da je značenje Z kao što je definirano u Zahtjevu 1.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HU0202001A HUP0202001A2 (hu) | 2002-06-14 | 2002-06-14 | DDP-IV gátló hatású azabiciklooktán- és nonánszármazékok |
PCT/HU2003/000041 WO2003106456A2 (en) | 2002-06-14 | 2003-06-11 | New compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20050027A2 true HRP20050027A2 (en) | 2006-02-28 |
Family
ID=90001551
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20050027A HRP20050027A2 (en) | 2002-06-14 | 2005-01-11 | Azabicyclo-octane and nonane derivatives with ddp-iv inhibiting activity |
Country Status (21)
Country | Link |
---|---|
US (2) | US7781455B2 (hr) |
EP (1) | EP1517907B1 (hr) |
JP (1) | JP4502804B2 (hr) |
KR (1) | KR100756761B1 (hr) |
CN (1) | CN100347170C (hr) |
AT (1) | ATE495162T1 (hr) |
AU (1) | AU2003244880B2 (hr) |
BR (1) | BR0311771A (hr) |
DE (1) | DE60335717D1 (hr) |
EA (1) | EA008166B1 (hr) |
HR (1) | HRP20050027A2 (hr) |
HU (1) | HUP0202001A2 (hr) |
IL (1) | IL165434A0 (hr) |
IS (1) | IS7638A (hr) |
MX (1) | MXPA04012691A (hr) |
NO (1) | NO20050199L (hr) |
NZ (1) | NZ537633A (hr) |
PL (1) | PL372799A1 (hr) |
RS (1) | RS109104A (hr) |
WO (1) | WO2003106456A2 (hr) |
ZA (1) | ZA200409907B (hr) |
Families Citing this family (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1764458A (zh) * | 2003-03-26 | 2006-04-26 | 麦克公司 | 作为黑皮质素-4受体激动剂的双环哌啶衍生物 |
HU227684B1 (en) * | 2003-08-29 | 2011-11-28 | Sanofi Aventis | Adamantane and azabicyclo-octane and nonane derivatives and their use as dpp-iv inhibitors |
KR101130433B1 (ko) | 2004-02-05 | 2012-03-27 | 교린 세이야꾸 가부시키 가이샤 | 비시클로에스테르 유도체 |
EP1717225A4 (en) * | 2004-02-18 | 2009-10-21 | Kyorin Seiyaku Kk | BICYCLIC AMIDE DERIVATIVES |
EP1719757B1 (en) * | 2004-02-27 | 2013-10-09 | Kyorin Pharmaceutical Co., Ltd. | Bicyclo derivative |
AU2005329423A1 (en) | 2004-09-20 | 2006-09-28 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors |
WO2006034315A2 (en) | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes |
AR051202A1 (es) | 2004-09-20 | 2006-12-27 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa |
MX2007003321A (es) | 2004-09-20 | 2007-06-05 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y su uso como agentes terapeuticos. |
CN101083994A (zh) | 2004-09-20 | 2007-12-05 | 泽农医药公司 | 杂环衍生物及其用作硬脂酰CoA去饱和酶抑制剂的用途 |
US7951805B2 (en) | 2004-09-20 | 2011-05-31 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase |
CA2580845A1 (en) | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase |
DOP2006000008A (es) | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1 |
AU2006239929B2 (en) | 2005-04-22 | 2011-11-03 | Alantos Pharmaceuticals Holding, Inc. | Dipeptidyl peptidase-IV inhibitors |
BRPI0611187A2 (pt) | 2005-06-03 | 2010-08-24 | Xenon Pharmaceuticals Inc | derivados aminotiazàis como inibidores da estearoil-coa desaturase humana |
MX2008001799A (es) * | 2005-08-11 | 2008-04-16 | Hoffmann La Roche | Composicion farmaceutica que comprende un inhibidor de dipeptidil peptidasa iv. |
KR20080042135A (ko) * | 2005-08-19 | 2008-05-14 | 엘란 파마슈티칼스, 인크. | 감마 세크레타제 억제제로서의 브릿징된 n비사이클릭설폰아미도 |
WO2007033350A1 (en) | 2005-09-14 | 2007-03-22 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors for treating diabetes |
EP1924567B1 (en) | 2005-09-16 | 2012-08-22 | Takeda Pharmaceutical Company Limited | Process for the preparation of pyrimidinedione derivatives |
GB0526291D0 (en) | 2005-12-23 | 2006-02-01 | Prosidion Ltd | Therapeutic method |
US20090156465A1 (en) | 2005-12-30 | 2009-06-18 | Sattigeri Jitendra A | Derivatives of beta-amino acid as dipeptidyl peptidase-iv inhibitors |
CN101395131B (zh) * | 2006-03-08 | 2012-11-14 | 杏林制药株式会社 | 氨基乙酰基吡咯烷甲腈衍生物的制备方法及其制备中间体 |
WO2007112347A1 (en) | 2006-03-28 | 2007-10-04 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
PE20071221A1 (es) | 2006-04-11 | 2007-12-14 | Arena Pharm Inc | Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas |
TW200811158A (en) | 2006-06-27 | 2008-03-01 | Sanofi Aventis | Piperidine or pyrrolidine urea derivatives, their preparation and their therapeutic application |
TW200811170A (en) | 2006-06-27 | 2008-03-01 | Sanofi Aventis | Urea derivatives of tropane, their preparation and their therapeutic application |
FR2902791B1 (fr) * | 2006-06-27 | 2008-08-22 | Sanofi Aventis Sa | Derives d'urees de tropane,leur preparation et leur application en therapeutique |
RU2009108280A (ru) | 2006-08-08 | 2010-09-20 | Санофи-Авентис (Fr) | Ариламиноарилалкилзамещенные имидазолидин-2,4-дионы, способы их получения, содержащие эти соединения лекарственные средства и их применение |
US8324383B2 (en) | 2006-09-13 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile |
TW200838536A (en) | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
DE102007005045B4 (de) | 2007-01-26 | 2008-12-18 | Sanofi-Aventis | Phenothiazin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
US8093236B2 (en) | 2007-03-13 | 2012-01-10 | Takeda Pharmaceuticals Company Limited | Weekly administration of dipeptidyl peptidase inhibitors |
JPWO2008114857A1 (ja) * | 2007-03-22 | 2010-07-08 | 杏林製薬株式会社 | アミノアセチルピロリジンカルボニトリル誘導体の製造方法 |
GB0713602D0 (en) * | 2007-07-12 | 2007-08-22 | Syngenta Participations Ag | Chemical compounds |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
MX2010004493A (es) * | 2007-10-25 | 2010-06-11 | Exelixis Inc | Compuestos de tropano. |
EP2146210A1 (en) | 2008-04-07 | 2010-01-20 | Arena Pharmaceuticals, Inc. | Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY |
WO2010003624A2 (en) | 2008-07-09 | 2010-01-14 | Sanofi-Aventis | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
CA2732984A1 (en) * | 2008-08-07 | 2010-02-11 | Kyorin Pharmaceutical Co., Ltd. | Process for production of bicyclo[2.2.2]octylamine derivative |
CN102186474A (zh) * | 2008-08-14 | 2011-09-14 | 杏林制药株式会社 | 稳定的医药组合物 |
WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
AR077642A1 (es) | 2009-07-09 | 2011-09-14 | Arena Pharm Inc | Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo |
WO2011023754A1 (en) | 2009-08-26 | 2011-03-03 | Sanofi-Aventis | Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
CN102918027A (zh) | 2010-04-06 | 2013-02-06 | 艾尼纳制药公司 | Gpr119受体调节剂和对与所述受体有关的障碍的治疗 |
EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
AU2011305525B2 (en) | 2010-09-22 | 2016-08-18 | Arena Pharmaceuticals, Inc. | Modulators of the GPR119 receptor and the treatment of disorders related thereto |
US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
US8901114B2 (en) | 2011-03-08 | 2014-12-02 | Sanofi | Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof |
WO2012120051A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
EP2683702B1 (de) | 2011-03-08 | 2014-12-24 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
US8895547B2 (en) | 2011-03-08 | 2014-11-25 | Sanofi | Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
EP2683699B1 (de) | 2011-03-08 | 2015-06-24 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
EP2683701B1 (de) | 2011-03-08 | 2014-12-24 | Sanofi | Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
US20140018371A1 (en) | 2011-04-01 | 2014-01-16 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
US20140066369A1 (en) | 2011-04-19 | 2014-03-06 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
WO2012145604A1 (en) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012145603A1 (en) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012170702A1 (en) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013055910A1 (en) | 2011-10-12 | 2013-04-18 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
EP2911655A1 (en) | 2012-10-24 | 2015-09-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Tpl2 kinase inhibitors for preventing or treating diabetes and for promoting -cell survival |
WO2014074668A1 (en) | 2012-11-08 | 2014-05-15 | Arena Pharmaceuticals, Inc. | Modulators of gpr119 and the treatment of disorders related thereto |
CA2979033A1 (en) | 2015-03-09 | 2016-09-15 | Intekrin Therapeutics, Inc. | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy |
ES2805743T3 (es) | 2015-03-24 | 2021-02-15 | Inst Nat Sante Rech Med | Método y composición farmacéutica para uso en el tratamiento de la diabetes |
CN110996951A (zh) | 2017-04-03 | 2020-04-10 | 科赫罗斯生物科学股份有限公司 | 治疗进行性核上性麻痹的PPARγ激动剂 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5592384A (en) * | 1978-12-30 | 1980-07-12 | Beecham Group Ltd | Compound having pharmacological activity |
IL59004A0 (en) * | 1978-12-30 | 1980-03-31 | Beecham Group Ltd | Substituted benzamides their preparation and pharmaceutical compositions containing them |
TW492957B (en) * | 1996-11-07 | 2002-07-01 | Novartis Ag | N-substituted 2-cyanopyrrolidnes |
WO2001034594A1 (en) * | 1999-11-12 | 2001-05-17 | Guilford Pharmaceuticals, Inc. | Dipeptidyl peptidase iv inhibitors and methods of making and using dipeptidyl peptidase iv inhibitors |
EP1254113A1 (en) | 2000-01-24 | 2002-11-06 | Novo Nordisk A/S | N-substituted 2-cyanopyroles and -pyrrolines which are inhibitors of the enzyme dpp-iv |
TW583185B (en) | 2000-06-13 | 2004-04-11 | Novartis Ag | N-(substituted glycyl)-2-cyanopyrrolidines and pharmaceutical composition for inhibiting dipeptidyl peptidase-IV (DPP-IV) or for the prevention or treatment of diseases or conditions associated with elevated levels of DPP-IV comprising the same |
KR100526091B1 (ko) * | 2000-10-06 | 2005-11-08 | 다나베 세이야꾸 가부시키가이샤 | 지방족 질소 함유 오원환 화합물 |
ATE370943T1 (de) | 2001-06-27 | 2007-09-15 | Smithkline Beecham Corp | Fluoropyrrolidine als dipeptidyl-peptidase inhibitoren |
HUP0200849A2 (hu) * | 2002-03-06 | 2004-08-30 | Sanofi-Synthelabo | N-aminoacetil-2-ciano-pirrolidin-származékok, e vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra |
-
2002
- 2002-06-14 HU HU0202001A patent/HUP0202001A2/hu unknown
-
2003
- 2003-06-11 MX MXPA04012691A patent/MXPA04012691A/es active IP Right Grant
- 2003-06-11 WO PCT/HU2003/000041 patent/WO2003106456A2/en active Application Filing
- 2003-06-11 AU AU2003244880A patent/AU2003244880B2/en not_active Ceased
- 2003-06-11 NZ NZ537633A patent/NZ537633A/en unknown
- 2003-06-11 KR KR1020047020277A patent/KR100756761B1/ko not_active IP Right Cessation
- 2003-06-11 CN CNB038138581A patent/CN100347170C/zh not_active Expired - Fee Related
- 2003-06-11 DE DE60335717T patent/DE60335717D1/de not_active Expired - Lifetime
- 2003-06-11 BR BR0311771-5A patent/BR0311771A/pt not_active IP Right Cessation
- 2003-06-11 RS YUP-1091/04A patent/RS109104A/sr unknown
- 2003-06-11 AT AT03738355T patent/ATE495162T1/de not_active IP Right Cessation
- 2003-06-11 PL PL03372799A patent/PL372799A1/xx not_active Application Discontinuation
- 2003-06-11 US US10/518,114 patent/US7781455B2/en not_active Expired - Fee Related
- 2003-06-11 JP JP2004513288A patent/JP4502804B2/ja not_active Expired - Fee Related
- 2003-06-11 EP EP03738355A patent/EP1517907B1/en not_active Expired - Lifetime
- 2003-06-11 EA EA200500017A patent/EA008166B1/ru not_active IP Right Cessation
-
2004
- 2004-11-29 IL IL16543404A patent/IL165434A0/xx not_active IP Right Cessation
- 2004-12-07 ZA ZA200409907A patent/ZA200409907B/en unknown
-
2005
- 2005-01-11 HR HR20050027A patent/HRP20050027A2/hr not_active Application Discontinuation
- 2005-01-12 IS IS7638A patent/IS7638A/is unknown
- 2005-01-13 NO NO20050199A patent/NO20050199L/no not_active Application Discontinuation
-
2010
- 2010-07-07 US US12/831,771 patent/US20110118305A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN100347170C (zh) | 2007-11-07 |
US7781455B2 (en) | 2010-08-24 |
DE60335717D1 (de) | 2011-02-24 |
KR20050016551A (ko) | 2005-02-21 |
US20050153973A1 (en) | 2005-07-14 |
KR100756761B1 (ko) | 2007-09-07 |
NZ537633A (en) | 2006-08-31 |
JP4502804B2 (ja) | 2010-07-14 |
JP2005532369A (ja) | 2005-10-27 |
BR0311771A (pt) | 2005-03-29 |
ZA200409907B (en) | 2006-08-30 |
IL165434A0 (en) | 2006-01-15 |
NO20050199L (no) | 2005-03-04 |
IS7638A (is) | 2005-01-12 |
AU2003244880A1 (en) | 2003-12-31 |
MXPA04012691A (es) | 2005-08-15 |
EA200500017A1 (ru) | 2005-06-30 |
RS109104A (en) | 2007-02-05 |
EA008166B1 (ru) | 2007-04-27 |
EP1517907B1 (en) | 2011-01-12 |
WO2003106456A2 (en) | 2003-12-24 |
WO2003106456A3 (en) | 2004-03-04 |
HUP0202001A2 (hu) | 2005-08-29 |
EP1517907A2 (en) | 2005-03-30 |
PL372799A1 (en) | 2005-08-08 |
CN1662530A (zh) | 2005-08-31 |
AU2003244880B2 (en) | 2009-05-28 |
US20110118305A1 (en) | 2011-05-19 |
ATE495162T1 (de) | 2011-01-15 |
HUP0202001D0 (hr) | 2002-08-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20050027A2 (en) | Azabicyclo-octane and nonane derivatives with ddp-iv inhibiting activity | |
KR100977898B1 (ko) | 화합물 | |
AU2004268832B2 (en) | Adamantane and azabicyclo-octane and nonane derivatives, process of their preparation and their use as DPP-IV inhibitors | |
JP7157771B2 (ja) | ピラゾールmagl阻害剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A1OB | Publication of a patent application | ||
ARAI | Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application | ||
ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20070517 Year of fee payment: 5 |
|
OBST | Application withdrawn |